Evidence map›Paper›PMID 42374338›Full record

ArticleBMC pulmonary medicine2026

Prognostic impact of

Shuhei Yoshikawa, Takahiro Sato, Taku Komori, Junichi Nakamura, Osamu Manabe, Noriko Oyama-Manabe, Satonori Tsuneta, Hirokazu Kimura, Sakae Takenaka, Toshiyuki Nagai and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC pulmonary medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Shuhei YoshikawaDepartment of Respiratory Medicine, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
Takahiro SatoDepartment of Respiratory Medicine, Faculty of Medicine, Hokkaido University, Sapporo, Japan. takahirosato0716@med.hokudai.ac.jp.
Taku KomoriDepartment of Respiratory Medicine, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
Junichi NakamuraDepartment of Respiratory Medicine, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
Osamu ManabeDepartment of Radiology, Jichi Medical University Saitama Medical Center, Saitama, Japan.
Noriko Oyama-ManabeDepartment of Radiology, Jichi Medical University Saitama Medical Center, Saitama, Japan.
Satonori TsunetaDepartment of Diagnostic and Interventional Radiology, Hokkaido University Hospital, Sapporo, Japan.
Hirokazu KimuraDepartment of Respiratory Medicine, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
Sakae TakenakaDepartment of Cardiovascular Medicine, Faculty of Medicine, Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
Toshiyuki NagaiDepartment of Cardiovascular Medicine, Faculty of Medicine, Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
Toshihisa AnzaiDepartment of Cardiovascular Medicine, Faculty of Medicine, Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
Isao YokotaDepartment of Biostatistics, Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
Ichizo TsujinoDepartment of Respiratory Medicine, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
Satoshi KonnoDepartment of Respiratory Medicine, Faculty of Medicine, Hokkaido University, Sapporo, Japan.

Funding

the Japan Agency for Medical Research and Development 25ek0109794h0001
6 · The paper itself

Abstract

backgroundSarcoidosis is a systemic granulomatous disease, often affecting the lungs, with a generally favourable prognosis. However, some patients experience progressive disease, and cardiac involvement may worsen outcomes. Data on the clinical course and causes of death in pulmonary sarcoidosis (PS), particularly with coexisting cardiac sarcoidosis (CS), remain limited.

methodsWe retrospectively analysed patients with histologically confirmed PS. Baseline evaluations included chest X-ray and computed tomography, pulmonary function tests, and echocardiography. CS was diagnosed based on the findings of

resultsA total of 513 patients met the study criteria. The 3-, 5-, and 10-year survival rates were 98.2%, 97.0%, and 94.6%, respectively (median follow-up: 6.7 years). CS was diagnosed in 48 patients (9.4%), and survival was poorer in those with CS (p = 0.004 by log rank test). Multivariate analysis showed that CS was associated with increased all-cause mortality after adjustment for age or sex (age-adjusted hazard ratio 3.55, 95% CI 1.18-10.6; sex-adjusted hazard ratio 3.79, 95% CI 1.28-11.2). During follow-up, 21 patients (4.6%) died. Malignancy was the leading cause of death (n = 10, 48%), followed by cardiac death (n = 3, 14%) and respiratory failure (n = 3, 14%).

conclusionsIn this Japanese single-centre cohort of patients with predominantly mild histologically confirmed PS, CS identified through a screening-based diagnostic pathway was associated with increased all-cause mortality.

Indexed as

CardiomyopathiesPositron-Emission TomographySarcoidosis, PulmonaryAdultAgedEchocardiographyFemaleFluorodeoxyglucose F18HumansMagnetic Resonance ImagingMaleMiddle AgedMultivariate AnalysisPrognosisRadiopharmaceuticalsRetrospective StudiesFluorodeoxyglucose F18RadiopharmaceuticalsCardiac sarcoidosisPrognosisPulmonary sarcoidosisSurvival rate

Identifiers

PMID42374338
PMCPMC13579761

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.